Advertisement

Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population

Nadine Hein, Donald P. Cameron, Katherine M. Hannan, Nhu-Y N. Nguyen, Chun Yew Fong, Jirawas Sornkom, Meaghan Wall, Megan Pavy, Carleen Cullinane, Jeannine Diesch, Jennifer R. Devlin, Amee J. George, Elaine Sanij, Jaclyn Quin, Gretchen Poortinga, Inge Verbrugge, Adele Baker, Denis Drygin, Simon J. Harrison, James D. Rozario, Jason A. Powell, Stuart M. Pitson, Johannes Zuber, Ricky W. Johnstone, Mark A. Dawson, Mark A. Guthridge, Andrew Wei, Grant A. McArthur, Richard B. Pearson and Ross D. Hannan

Article Information

Citation 
vol. 129 no. 21 2882-2895
PubMed 

Print ISSN 
Online ISSN 
History 
  • Submitted May 24, 2016
  • Accepted February 22, 2017
  • Published online May 25, 2017.

Article Versions


Contributors 
  • Nadine Hein, 1Australian Cancer Research Foundation Department of Cancer Biology and Therapeutics, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia; 2Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia;
  • Donald P. Cameron, 1Australian Cancer Research Foundation Department of Cancer Biology and Therapeutics, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia; 2Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; 3Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia;
  • Katherine M. Hannan, 1Australian Cancer Research Foundation Department of Cancer Biology and Therapeutics, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia; 2Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; 4Department of Biochemistry and Molecular Biology, The University of Melbourne, Parkville, VIC, Australia;
  • Nhu-Y N. Nguyen, 5Australian Centre for Blood Diseases, Monash University, Melbourne, VIC, Australia;
  • Chun Yew Fong, 2Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; 3Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia; 6Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia;
  • Jirawas Sornkom, 2Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; 3Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia;
  • Meaghan Wall, 7Victorian Cancer Cytogenetics Service, St. Vincent’s Hospital, Fitzroy, VIC, Australia; 8Department of Medicine, St. Vincent’s Hospital, and
  • Megan Pavy, 1Australian Cancer Research Foundation Department of Cancer Biology and Therapeutics, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia;
  • Carleen Cullinane, 2Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; 3Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia;
  • Jeannine Diesch, 2Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia;
  • Jennifer R. Devlin, 2Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia;
  • Amee J. George, 1Australian Cancer Research Foundation Department of Cancer Biology and Therapeutics, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia; 9Department of Pathology, The University of Melbourne, Parkville, VIC, Australia; 10School of Medical Sciences, University of Queensland, St. Lucia, QLD, Australia;
  • Elaine Sanij, 2Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; 3Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia; 9Department of Pathology, The University of Melbourne, Parkville, VIC, Australia;
  • Jaclyn Quin, 2Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia;
  • Gretchen Poortinga, 2Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; 3Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia; 9Department of Pathology, The University of Melbourne, Parkville, VIC, Australia;
  • Inge Verbrugge, 11Division of Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands;
  • Adele Baker, 2Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia;
  • Denis Drygin, 12Pimera Inc, San Diego, CA;
  • Simon J. Harrison, 3Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia; 6Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia;
  • James D. Rozario, 13Clinical Haematology Unit, The Canberra Hospital, Canberra, ACT, Australia;
  • Jason A. Powell, 14Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia; 15Schools of Medicine and Biological Sciences, University of Adelaide, SA, Australia;
  • Stuart M. Pitson, 14Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia; 15Schools of Medicine and Biological Sciences, University of Adelaide, SA, Australia;
  • Johannes Zuber, 16Research Institute of Molecular Pathology, Vienna, Austria;
  • Ricky W. Johnstone, 2Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; 3Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia; 9Department of Pathology, The University of Melbourne, Parkville, VIC, Australia;
  • Mark A. Dawson, 2Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; 3Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia; 6Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia;
  • Mark A. Guthridge, 5Australian Centre for Blood Diseases, Monash University, Melbourne, VIC, Australia;
  • Andrew Wei, 5Australian Centre for Blood Diseases, Monash University, Melbourne, VIC, Australia; 17Department of Clinical Haematology, The Alfred Hospital, Melbourne, VIC, Australia; and
  • Grant A. McArthur, 2Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; 3Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia; 6Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia;
  • Richard B. Pearson, 2Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; 3Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia; 4Department of Biochemistry and Molecular Biology, The University of Melbourne, Parkville, VIC, Australia; 18Department of Biochemistry and Molecular Biology, Monash University, Melbourne, VIC, Australia
  • Ross D. Hannan, 1Australian Cancer Research Foundation Department of Cancer Biology and Therapeutics, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia; 2Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; 3Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia; 4Department of Biochemistry and Molecular Biology, The University of Melbourne, Parkville, VIC, Australia; 10School of Medical Sciences, University of Queensland, St. Lucia, QLD, Australia; 18Department of Biochemistry and Molecular Biology, Monash University, Melbourne, VIC, Australia

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output